drugset / Trial / NCT05944562
Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome
Phase 1
Active not recruiting
24 enrolled
Washington University School of Medicine
Daniel E. Corbin Jr. Lymphoma Fund · collabNovartis · collabSwim Across America · collabThe Foundation for Barnes-Jewish Hospital · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The hypotheses of this study are that single agent DZR123 will be safe and well tolerated in patients with advanced (stage IB-IVB) mycosis fungoides (MF)/Sézary syndrome (SS) who have had at least one prior systemic therapy, and that in these patients, DZR123 will demonstrate efficacy and be worth of further study.
Timeline
- Start
- 2024-01-09
- Primary completion
- 2027-02-28
- Completion
- 2029-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tulmimetostat | Small molecule | 200 mg | Oral |
| Subject | Tulmimetostat | Small molecule | 250 mg | Oral |
| Subject | Tulmimetostat | Small molecule | 300 mg | Oral |